Surgical Innovations Group expects flat annual revenues

Surgical Innovations Group's shares tumbled Tuesday after the company said 2012 revenues were hit by manufacturing capacity constraints and delays in regulatory approvals in the final quarter.

Surgical Innovations Group's shares tumbled Tuesday after the company said 2012 revenues were hit by manufacturing capacity constraints and delays in regulatory approvals in the final quarter.

Shares fell almost 15% on the morning of the announcement as the group said it expected total revenue last year to come to £7.6m, unchanged from 2011.

The designer and manufacturer of solutions for surgery said manufacturing capacity constraints its UK facility in Leeds and a delay in US regulatory approval impacted revenues towards the end of the financial year. As a result, revenues of £1.0m were not seen until January.

Nevertheless, trading improved 85% to £5.6m during the last half of the year, driven by an increase in product orders.

The company's SI Brand business represented 68% of overall revenues, compared to 62% in 2011.

Gross margins were anticipated to have improved by three basis points to 50.3%, up from 47.3% the year earlier.

Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) for the period was projected to reach £2.85m, up from £2.8m.

The firm ended the year with short term borrowings of £1.4m against bank facilities provided by HSBC of £2.0m.

Graham Bowland, Chief Executive Officer, said: "I am pleased with the strong sales performance that we've achieved in the second half of the year.

"There is no doubt that the manufacturing capacity constraints we experienced in the final quarter of 2012 justify the need for our proposed new facility part funded by the award of the £5.0m regional growth fund."

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Lab-grown meat: how “moo’s law” will drive innovation
Soft commodities

Lab-grown meat: how “moo’s law” will drive innovation

Jim Mellon and Anthony Chow, co-founders of Aim-listed Agronomics, explain why they believe that “cellular agriculture” will benefit from massive long…
16 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021